Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Mar 31, 2025 · 10-K · 90 days after period end · 0001213900-25-026371
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $23.00K |
| Net Income | -$6.65M | -$9.32M | -$10.65M | -$8.01M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end
